About OPi Group
OPi Group is a Healthcare company based in Dardilly (France) founded in 1999, and was acquired by EUSA Pharma in March 2007. Enzymatic therapeutics for rare and severe diseases are developed. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified.
Company details
Enzymatic therapeutics targeting rare and severe diseases are developed by OPi Group, which was founded in 1999 and is based in Dardilly, France. Operations focus on biotechnology within the pharmaceutical sector, with specific products including Kidrolase, derived from Escherichia coli L-asparaginase, and Erwinase, derived from Erwinia chrysanthemi L-asparaginase. These are utilized for patient treatment in orphan disease indications.
- Headquarters Dardilly, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website orphan-opi.com
- Acquired by EUSA Pharma (Mar 2007)
- Investors
- Acquired byEUSA Pharma
(Mar 2007)
Investors in OPi Group
OPi Group has secured backing from 1 investor. Prominent investors backing the company include EUSA Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer and commercializer of pharmaceutical medicines | 2006 | eusapharma.com | Hemel Hempstead, United Kingdom |
Investor details for OPi Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of OPi Group
2 dated milestones of OPi Group across 8 years, from founding to its latest funding, stage changes and deals.
- Founded OPi Group is founded.
- Exit Acquired by EUSA Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Opi Group
Complete news archive for OPi Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OPi Group
OPi Group was founded in 1999.
OPi Group is headquartered in Dardilly, France. It is registered at Dardilly, Rhone, France.
Enzymatic therapeutics targeting rare and severe diseases are developed by OPi Group, which was founded in 1999 and is based in Dardilly, France. Operations focus on biotechnology within the pharmaceutical sector, with specific products including Kidrolase, derived from Escherichia coli L-asparaginase, and Erwinase, derived from Erwinia chrysanthemi L-asparaginase. These are utilized for patient treatment in orphan disease indications.
OPi Group has 1 investor. Key investors include EUSA Pharma.
Yes. OPi Group was acquired by EUSA Pharma in March 2007.